Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2025 Jun; 19(3):1112. View Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. Abstract

Help Navigate the Process: Early Information and Communication About Late Effects of Pediatric and Adolescent Cancer. JCO Oncol Pract. 2025 Mar 20; OP2400841. View Help Navigate the Process: Early Information and Communication About Late Effects of Pediatric and Adolescent Cancer. Abstract

Impact of Persistent Alopecia on Quality of Life in Childhood Cancer and Transplant Survivors. Pediatr Blood Cancer. 2025 Feb; 72(2):e31432. View Impact of Persistent Alopecia on Quality of Life in Childhood Cancer and Transplant Survivors. Abstract

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Blood Cancer J. 2024 10 31; 14(1):191. View Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Abstract

Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. Lancet Child Adolesc Health. 2024 10; 8(10):740-750. View Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. Abstract

Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2024 02; 18(1):34-41. View Cancer survivorship programs at the Dana-Farber Cancer Institute. Abstract

Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review. Pediatr Blood Cancer. 2024 Apr; 71(4):e30881. View Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review. Abstract

Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024 03; 38(3):482-490. View Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Abstract

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023 09 26; 7(18):5234-5245. View Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Abstract

Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. Pediatr Blood Cancer. 2023 11; 70(11):e30560. View Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. Abstract

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023 04 11; 7(7):1092-1102. View Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Abstract

Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. J Clin Oncol. 2023 04 20; 41(12):2248-2257. View Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. Abstract

Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia. Support Care Cancer. 2023 Jan 10; 31(2):109. View Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia. Abstract

Predicting chronic morbidity in childhood cancer survivors. Nat Med. 2022 08; 28(8):1539-1540. View Predicting chronic morbidity in childhood cancer survivors. Abstract

Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. Br J Haematol. 2022 08; 198(3):421-430. View Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. Abstract

Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis. J Pediatr Gastroenterol Nutr. 2022 Mar 01; 74(3):402-407. View Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis. Abstract

Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev. 2022 Mar 01; 31(3):536-542. View Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. Abstract

Large Anterior Mediastinal Mass and Cardiac Infiltration at Diagnosis in a Child With T-cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2022 Mar 01; 44(2):e418-e419. View Large Anterior Mediastinal Mass and Cardiac Infiltration at Diagnosis in a Child With T-cell Acute Lymphoblastic Leukemia. Abstract

Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Adv. 2022 01 11; 6(1):72-81. View Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Abstract

Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group. Eur J Cancer. 2022 02; 162:65-75. View Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group. Abstract

Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration. Pediatr Blood Cancer. 2022 07; 69(7):e29505. View Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration. Abstract

Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer. 2022 02 15; 128(4):788-796. View Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Abstract

Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes Endocrinol. 2021 09; 9(9):622-637. View Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Abstract

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 11 01; 39(31):3496-3505. View Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. Abstract

Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. Lancet Haematol. 2021 Jul; 8(7):e513-e523. View Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. Abstract

Pediatric primary cutaneous anaplastic large cell lymphoma treated with brachytherapy. Pediatr Dermatol. 2021 May; 38(3):712-713. View Pediatric primary cutaneous anaplastic large cell lymphoma treated with brachytherapy. Abstract

Virtual visits as long-term follow-up care for childhood cancer survivors: Patient and provider satisfaction during the COVID-19 pandemic. Pediatr Blood Cancer. 2021 06; 68(6):e28927. View Virtual visits as long-term follow-up care for childhood cancer survivors: Patient and provider satisfaction during the COVID-19 pandemic. Abstract

Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885. View Corrigendum. Abstract

Risk factors for steroid-induced affective disorder in children with leukemia. Pediatr Blood Cancer. 2021 05; 68(5):e28847. View Risk factors for steroid-induced affective disorder in children with leukemia. Abstract

Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719. View Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Abstract

Long-Term Psychosocial Well-Being and Quality of Life Among Childhood Cancer Survivors Who Developed a Subsequent Malignant Neoplasm. J Adolesc Young Adult Oncol. 2021 04; 10(2):240-245. View Long-Term Psychosocial Well-Being and Quality of Life Among Childhood Cancer Survivors Who Developed a Subsequent Malignant Neoplasm. Abstract

Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020 05 12; 4(9):2084-2094. View Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Abstract

Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458. View Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Abstract

Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017 09; 18(9):1238-1248. View Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Abstract

Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1327-1334. View Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Abstract

A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Jul; 64(7). View A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Abstract

Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Support Care Cancer. 2017 02; 25(2):449-457. View Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Abstract

Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Curr Hematol Malig Rep. 2016 10; 11(5):385-94. View Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Abstract

Fatigue in adolescent and adult survivors of non-CNS childhood cancer: a report from project REACH. Support Care Cancer. 2016 09; 24(9):3951-9. View Fatigue in adolescent and adult survivors of non-CNS childhood cancer: a report from project REACH. Abstract

Adapted Delivery of Cognitive-Behavioral Treatment for Insomnia in Adolescent and Young Adult Cancer Survivors: A Pilot Study. Behav Sleep Med. 2017 Jul-Aug; 15(4):288-301. View Adapted Delivery of Cognitive-Behavioral Treatment for Insomnia in Adolescent and Young Adult Cancer Survivors: A Pilot Study. Abstract

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016 Mar; 101(3):279-85. View Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Abstract

Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016 Mar 15; 122(6):946-53. View Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Abstract

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90. View Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Abstract

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016 Feb; 63(2):228-33. View Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Abstract

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10. View Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Abstract

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun; 47(9):1373-9. View The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Abstract

25-hydroxy vitamin D deficiency following pediatric hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2011 May; 17(5):749-53. View 25-hydroxy vitamin D deficiency following pediatric hematopoietic stem cell transplant. Abstract

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb; 54(2):199-205. View Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Abstract

Health status of the oldest adult survivors of cancer during childhood. Cancer. 2010 Jan 15; 116(2):497-505. View Health status of the oldest adult survivors of cancer during childhood. Abstract

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18; 115(7):1351-3. View Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Abstract

Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009 Feb; 21(1):1-8. View Childhood acute lymphoblastic leukemia: update on prognostic factors. Abstract

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 01; 26(7):1106-11. View Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. Abstract